In an integrative approach to treating Alzheimer’s Disease and other associated Diseases, the reliability of memory and a person’s ability to articulate perfect judgment is one of the significant elements that determine a person’s real life. On many occasions, people who develop problems usually are considered unhealthy and suffer from one or many different diseases. Once a disease affects a person initially termed as usual, the person’s reaction changes. Battling diseases by human beings creates significant challenges in today’s life, thereby calling for considerations in the attention to treat the intended infection that affects the particular individual.
As a result, a study by Scheltens et al. (2021) stipulates that one of the most viral and severe issues in the life of an ageing man is Alzheimer’s Disease, commonly known as AD. AD is, by nature, a progressive issue that lies on neurodegenerations causing significant impairment in the person’s memory and the effect of cognitive judgment in both males and females. AD is generally considered to be the most preferable leading effect in the cause of the problem of dementia. This problem is majorly noticed in people of greater age, considered the older category of individuals in their late adulthood. Such people experience hardship in life and live like children since they tend to return to life where they need more support from the most energetic people under their youthful age category (Rahm, 2023). The disease relates closely to the burden of social life that emphasizes the significant life of the society, thereby increasing the existing rates of morbidity and issues of mortality that seem to affect mainly the elderly category of people.
The increased number of older people, mainly in the more significant parts of the United States, facilitates the progressive realization of Alzheimer’s disease. There is a need to consider regular diagnosis and treatment through various approaches, thereby allowing individuals with AD to perform cognitively and functionally. Due to the complexity of complications brought about by the techniques of medication, Khan et al. (2022) found that treatment of AD, which is age-related, requires good exercise by the old. One must ensure that good exercise is undertaken daily to allow the body to get used to being active and perform many activities without unnecessary support. Indeed, many older adults have prioritised regular exercise to ensure that their body parts do not end up in a situation where they cannot move. The degree of regular exercise is the preliminary requirement from medical institutions as a pre-clinical treatment technique for all the affected persons (Ketskes, 2023). This technique’s applicability occurs both at the early clinical stage and the late stage of AD. It has likely helped in reducing the rate, thereby a strategy to facilitate prevention.
During regular exercise, the person facilitates an easy flow of blood in the brain, which increases the volume of the body’s hippocampal and improves the body’s neurogenetic elements. In various prospective research studies conducted on AD, there are several indications that circumstances of a person’s failure to undertake physical inactivity led to higher chances of the risk of the disease. According to the Alzheimer’s Association (2016), the AD development rate is only reduced through the performance of regular exercise as a technique to minimize the associated risk issues and concerns. Therefore, the improved rate of a person’s cognitive function depends on the exercise rate. This similarly promotes the decrease in the symptoms associated with the neuropsychiatric disease, thereby slowing and declining daily activities in the life of a living individual. Amidst the actualization of the activities in old age, there will be indications that the patient or the person experiences a reduced rate of the side effects associated with the disease, thus the preference for adherence to the instructions on exercise rather than medical attention in the healthcare setup. The approaches to integrative treatment of the disease are both traditional and modern or non-traditional, providing the application from the plants to medical chemistry.
Pharmacological Approaches to Treatment
Application through pharmacy has played a significant role in the treatment of AD. Pharmaceutical approaches allow using various medicinal elements to curb the channels caused by AD (Rahm, 2023). Considerable, on the review of many kinds of literature, AD, the age of the ageing category of individuals, is highly represented by the disease across the nation and globally. Due to the variety of advances in medical considerations, there is an increased life expectancy rate among the country’s residents. In an advanced estimation of the constitution of the age in the United States, it is speculated that most Americans will be more than 65 years old, an estimation of more than 20 % of the country’s total population (Morello et al., 2018). As a result, it is relatively accurate that the estimated population will be affected by AD and subjected to a higher risk of increased dementia-related issues. In general studies, the most common and relatable disease to dementia as associated with age is AD. The disease progressively starts in a person through the effect of memory loss and advances to the difficulty of remembering the most essential issues. This can easily be noticed in conversations with such individuals where they tend to forget the simple matters in response to the existing environment to know which tablets best fit the patient with AD.
Cholinesterase inhibition
In the early stages of a patient with AD, the cholinesterase through cholinergic systems affects the processing rate of the memory (Rahm, 2023). This can best be treated by applying the cholinesterase approach of inhibitors. Cialis works tirelessly to prevent the effects that cause the breakdown of acetylcholine in the human body of patients with AD. Similarly, AD is a disease that engages the infection and affections to control the parts of the brain, extending to memory and later affecting the ability of a person in the language sector. It causes significant effects on the manner and rate at which one can conduct daily activities, which in the early stages used to be easy tasks to perform. More than 6.6 million citizens of the American state in the age of 65 years and above live under the influence of Alzheimer’s Disease (Ryan & Nolan, 2016). Among the category, most individuals are 75 years older, constituting more than 75 per cent of the older people. This proves the notability that dementia is a problem that is directly and closely related and caused by the issues of age, which accounts for an estimation of between 65 to 85 % of the cases (Ketskes, 2023). Since ageing is one of the significant risk factors in the development of AD, the associated estimation of the disease ranges between 81 % as a minimum concerning the individuals with AD and the age bracket starting from 75 years and above.
Subsequently, treatment occurs through processes that include Tacrine, Donepezil, Rivastigmine, and Galantamine. There is much significance in considering age as a population factor to determine the effectiveness and impacts of AD. In the official records in the United States, the increased rate of deaths indicates about 70 % caused by the effect of AD in the period between 200 to 2013, a duration of 13 years (Scheltens et al., 2021). Compared to the effects of heart diseases, there is a decrease of more than 14 % within the same time frame and at the same consideration. The rise of AD has kept it in the category of the most considered diseases in the history of the United States. This creates a significant burden in the healthcare sector since older people must be given attention by energetic people and get support to sustain their healthcare standards. The rise in AD issues within ten years increasingly moved from position 32 to nearly the 12th position. This also extended to the increase in the number of death rates recorded in the system from 32 to the 9th position, raising alarm in the United States healthcare sector and the future of the country. It is denoted that this was the highest recorded rate within a short interval in the history of lost life.
Donepezil (Aricept, Aricept ODT)
On the other hand, Donepezil is another form of indication to treat dementia in AD. AD has many challenges when it comes to diagnosis procedures and any other consideration for treatment purposes. There is a mixture in the disease effectiveness during treatment since it is an issue that relates to age and not any other common problem in the healthcare sector. As a result, Donepezil treats both patients with a mild level of AD and moderate a patient with the disease (Ketskes, 2023). In the treatment process, inhibitors are selected to minimize the rate of the acetylcholinesterase enzyme that destroys acetylcholine, improving the high level of acetylcholine in the patient. Patients are recommended for the doses at the mild stage to take between 5 to 10 mg daily, while those with mild to severe range from 23 mg per day but are administered once.
Rivastigmine (Exelon, Exelon Patch)
This type of treatment applies to the mild AD. The maximum dose is 12mg per day but at a rate of 1.5 per dose to the patient. AcHE inhibitor is considered to be an irreversible pseudo known as rivastigmine (Ketskés & Rahm, 2023). It is not easy to find reliable solutions to matters about nature since the ageing factor is a natural problem. Once a person becomes old, they return to a distinction by nature. According to Khan et al. (2022), the only available solution is to ensure that techniques are in place to make such older adults live longer than expected but not possibly treat the disease of being old. Even though the actual and accurate techniques and mechanisms for the rivastigmine are not identified, the application of the doses gives fair effects. It enhances cholinergic function, thereby relating to therapeutic effects to the patient with AD, increasing the level of acetylcholine and reversible inhibitors of cholinesterase hydrolysis. In the early stages of AD at preclinical periods, there might be minimum solutions for regulating the treatment of AD at preliminary stages, which also extend to the mild cognitive impairment problem commonly known as MCI. The MCI significantly entails a significant cognitive decline in an impaired syndrome as a result of one’s ageing effects. This also affects the level of a person’s education without affecting the issues of one’s significant activities in daily life. Research shows that the progressive nature of AD from the MCI constitutes about five years or less (Ketskes, 2023).
Galantamine (Razadyne, Razadyne ER)
This offers to treat mild to moderate AD in the patient, enhancing cholinergic function and aCHe inhibitors. No study has been conducted to prove that it alters the processes of dementia in the patient’s body. Administering the dose requires that at least 4mg be given twice to the patient daily and maintained between 16 and 24 mg daily after titration. In exercising the need for medication, the potential is significantly vested in the techniques applicable for the general treatment. The interest has been shifted to the nonpharmacological technique of AD treatment in close consideration of the side effects. Some essential treatments include cognitive training and general cognitive stimulation, demonstrating the benefits of mixed reactions and inconsistencies in general outcomes. To prevent the three diseases, one has to perform various exercises (Alzheimer’s, 2016).
Tacrine
This was the first method and technique of AD Treatment to be approved to help patients with the range of mild to moderate dementia. It involves hepatoxicity, which is not applicable in the modern context. It is the most significant inhibitor to prevent the availability and operations of AChE. The exercises have proved to reduce and prevent the issues of early affection and advance the treatment of dementia, AD, and MCI (Guzman et al.,2021). This research article significantly provides a relevant review of new field studies and considers other relevant recommendations to help patients with AD issues. Tacrine is an inhibitor of AChE and BChE but is highly effective in inhibiting AChE in patients undergoing dementia issues, thus AD.
N-Methyl-D-Aspartate Antagonists
Memantine is the only drug approved in this context for the administration and treatment of AD in the United States (Ketskés & Rahm, 2023). The drug can be administered solely or mixed with AChE to the patient. Since one gets older due to a lapse in time, the AD problem similarly worsens over time. There are many stages of experiences with different degrees of affection in people who undergo such a problem. One effect might be more potent at one stage than the other, even though both have the same problem brought about by AD in a progressive manner. The improvement of symptoms comes after a worsening condition. Before any form of treatment is found by medical experts, the effectiveness of this disease will keep increasing in the number of people in the old age category (Bakulski et al., 2020). The treatment of the disease is the only option to kill its ability to thrive amongst older adults. In the early stages of the AD problem, there are difficulties experienced in a high rate of loss of memory and individual issues of cognitive impairment in judgment ability. However, these occur in stages, and gradually, appearance grows in the person and a systematic order within the family. At this early stage, the family should consider a keen diagnosis of the disease. The earlier the diagnosis, the safer the patient since the growth of the disease at a gradual pace can create more difficulty in the effort to perform the treatment.
Memantine (Namenda, Namenda XR)
AD patients get approval for dementia treatment at a rate between moderate to severe. Through titration to about 20 mg daily, the recommendation for a primary dose at the beginning is administered at 5 mg daily. During the middle stage of AD growth, the person has brain damage. The dose can further be extended from 5 to 7 mg daily, and through titration, it can be extended from 20 to 28 mg daily, thereby giving effective changes to the patient (Ketskés & Rahm, 2023). A damaged brain hinders the understanding and communication elements such as language fluency, inability to exercise perfect reasoning, poor processing in the sensory organs, and the person’s thought is below the standard of a reasonable person. As a result of the drug administration, patients tend to have side effects such as feeling dizzy, nausea, agitation, severe headache, constipation during long calls, and general confusion.
In the middle stage, most victims undergo serious confusion in life, where there is severe difficulty in identifying, recognizing, and remembering the names of ordinary family members and close friends (Scheltens et al., 2021). In most cases, fathers and mothers tend to forget the names and identities of their sons, daughters, and grandchildren. The last stage comes after the middle stage and consists of an enormously grown AD issue. The patient at this particular stage cannot hold successful communication with people, shift the dependency ratio to rely on other people for general support and survivorship, and mostly spend much of their time in bed. At this moment, the AD has grown more potent than the body response, and the person feels like the body is shutting down, thus the acceptance.
Treatment of moderate to severe disease
At this stage, NMDA improves the signal-to-noise ratio in the glutamatergic aspect. Blockage by calcium caused as an effect of NMDA minimizes the effects of brain damage through the nerve, preventing the accumulation of intercellular calcium. Patients with similar problems are advised to ensure that one should have a reliable personal doctor besides the diagnosis. Such medical attention from the clinics provides large areas of treatment to the patient, which minimizes the chances of other infections in an individual. The method and willingness to obtain primary medical attention facilitate the maximization of patient care, family also plays a role in the emphasis, and medical neuropsychiatric background also provides a reasonable basis for the importance of acquiring a personal doctor (Farina et al., 2014). There should also be a visit to the laboratories for a routine to rule out unnecessary thoughts of other causes, thereby giving an accurate response to the target treatment. The causes of dementia involve complete human blood count, a comprehensive panel of metabolic body reactions, stimulation of thyroid hormones, presence of vitamin B12 in the body, and folic acidic reactions.
Other considerations in the case include the neuroimaging process using a magnetic resonance imaging machine (MRI) as a workout in the routine for the patient’s safety. Strengthening of such diagnosis is done through testing by neuropsychological method and necessary serological approaches as an application for the biomarkers (Forbes et al., 2015). Obtaining the exposure of the medical biomarkers depends on the serum and the sources of cerebral spinal body fluid known as CSF. There is a higher accuracy in the results obtained when one uses the CSF, giving a sensitivity and specification of over 85 to 90 per cent. Currently, the treatment of the infection relies on pharmacological applications involving inhibitors such as acetylcholinesterase and meth amine known as methyl D-Aspartate antagonists acting as body receptors in the treatment.
The General Review of the Alzheimer’s Disease
As discussed in the introductory section, AD is an issue that occurs as a progressive disease, and it is naturally neurodegenerative, causing severe effects in memory impairment and a person’s cognitive judgment. In one’s late adulthood lifestyle, AD is the most probable disease that facilitates the cause of dementia (Morello et al., 2018). Some of its characteristics are based on the neuropathology and general research findings that dwell on intracellular neurofibrillary body tangles. It also relates to the plagues, which consist of depositing the human body’s protein amyloids. It is, however, essential to note that not all individuals with issues of prototypical neuropathology have the actual manifestations, signs, and symptoms associated with diseases such as dementia and AD in clinical environments.
Additionally, problems of memory loss exist as the initial signs and symptoms associated with AD. The most exciting part is that the symptoms of the disease vary from one individual to the other. In the aspect of the description, Bakulski et al. (2020) found that there is a word finding understanding or the concept of problems of having to remember a point or an essential discussion compared to other individuals who fall within the same age category. In such conversations, one realizes they need help in the regular and common language, which extends to the problem of needing to remember essential concepts quickly. The problem is compared to people of the sage age brackets who can perform the remembrance other than the victim. Spatial issues and problems associated with vision extend to the inability to emphasize the awareness between such affected individuals (Guzman et al., 2021). The decisions made by older people with such problems also lie significantly on the problems of impaired reasoning, judgment, and general thoughts of the mind.
Besides the two significant symptoms, one with an AD problem can also experience signs such as behavioural change. Some changes in the person’s behaviour make them take much time to complete simple, regular, and easy tasks, thereby delaying performance. In everyday conversations, most people tend to show problems of repeating issues and common questions that are subsequently easy to listen to and understand (Khan et al., 2022). There are also problems associated with handling small and petty cash, paying bills, and counting money, which affects the category of individuals. Another notable sign amongst such individuals is that when they forget simple things, they tend to forget where they came from and get lost while wandering. Older people with AD problems also misplace items and need help remembering where they are; they might look for what they are carrying and take time to remember that they are holding the items at odd times and places. It is also a consideration that their moods keep changing even at times when nobody has wronged them, extending to the personality traits, increasing anxiety, and many tend to be aggressive over issues that are not closely related to the individual feelings of aggressiveness.
In the concept of remembering information in new communications, the systems of the symptoms vary from one person to another (Ketskés & Rahm, 2023). Most importantly, this is the most critical scenario where a person loses memory, leading to difficulty or inability to remember important things, just like forgetting your family members. As a result of the death and malfunctioning of many of the million neurons in the human brain, the person similarly suffers some severe, extended side effects and general symptoms of the same disease. Some of these symptoms include the development of loss in memory, affecting the performance rate of one’s daily living activities, commonly abbreviated as ADL (Bailey, 2013). The individuals also experience challenges in facilitating problem-solving techniques, orientation methods practices, and relationships to visual-spatial matters. In the event, there are also issues of neuropsychiatric problems like changes in the person’s mood swings, personality towards people, and things in the concept of bad attitudes. The effects rate also differs from one individual to the other regardless of the similarity in age.
Surprisingly, there are reports that scientists still need to manage to establish the actual cause of AD in many individuals. Some of the initial causes only relate to combined changes in the brain due to ageing. There is also the consideration that AD is an issue in the genetic relations of people of the same family. Many of the diseases are also affected by environmental issues, thereby formulating part of the causes that scientists have not established (Barnes, 2015). Similarly, factors of lifestyle are also necessitated in the cause of AD since individuals who do not live a balanced diet tend to get old faster, thereby easily affected by the effects of the disease. The life of an individual is founded on living healthy. A healthy life depends on issues and considerations such as proper medical care, good exercise, and eating a balanced diet to provide the body with sufficient nutrients to perform its functions (Bakulski et al., 2020). When the body actively responds to the tasks, the immunity tends to be intense, persistent, and resistant to any form of infection and general difficulty.
The increase and decrease rates that risk AD infection depend solely on the person’s genetic consideration and immunity system. Just like the other serious problems that people undergo in the healthcare system, AD is an issue that similarly occurs progressively, affecting one’s brain gradually. After losing neurons in one’s brain, several behavioural changes will be experienced. This only applies to people who, in most cases, have reached a particular age. Experiences of life change in one’s brain lead to severe issues of irrationality in general thinking and behaviour. The alterations cause effects through amyloid plagues with the effects of neurofibrillary problems and the tau tangles resulting in various losses of each neuron (Nelson et al., 2007). The loss also touches on the number of connections and communications by the same factors, requiring immediate consideration. Therefore, the person needs help living an independent life, reasoning, and remembering most of the essential information, making communicating difficult.
Interestingly, AD is not explicitly caused by the effects of old age, as many researchers and people tend to think before the finalization of the actual outcome. Indeed, there is a very close link and relationship, but it is not the cause. However, it is considered one of the most probable risk elements that factors the cause of the disease since most of the existing features are based on the impacts of old age, therefore the suspicion (Khan et al., 2022). From the reliable records of the United States, the record of individuals suffering from severe AD imposes a rapid increase in 5 years. The increase rates affect a majority of people aged 65 years and above. In the record of individuals aged 85 years and above, it is noted that more than 30 per cent of the individuals are affected by AD.
According to Bakulski et al. (2020), studies are underway, and scientists work tirelessly to ensure sufficient research studies to discover the changes and control the impacts caused on the brain. The changes affecting the brain and the issues related to age bring alterations and end up killing the brain nerves and neurons, which extend to more cells dying in the brain, thereby leading to the issues of AD. The natural, in-depth effect is noted in the shrinking of the brain sections through atrophy, severe problems of inflammation, and instability in the process and results of molecular production. More issues include vascular body damage after the free radicles effect and cell breakdown in energy production, altering many operations. It is, therefore, considerable and logical that age issues are not only the cause but also one of the most probable factors that an individual may risk getting problems with AD (Buchman et al., 2012). In rare circumstances and life today, few individuals in the United States live for more than 90 years without undergoing the problems of dementia, which only happens in circumstances in which the relevant measures are put into consideration.
As it is considered that age emerges as the most significant and most possible risk factor for AD, the chances of a person getting AD due to age are minimal. The rate is not more than 1 per cent as a result of mutation of genes through the formulated proteins under amyloid precursor. The rate that dominates between 40 to 65 per cent of the victims of AD also stands a chance of suffering from alterations in the relationship with the gene commonly known as APOE e4 (Scheltens et al., 2021). History of the family, which also simulates the issues of genes, risk factors associated with cardiovascular disease infections, preexisting issues of prior MCI, too much brain work through the standard of education, different engagement levels such as cognitive and social, and the traumatic disorders that are caused by general or severe injury.
This proves that in many cases that lead to the effect of AD, there is no one particular cause. The genetic causes are numerous and can multiply with time, leading to one becoming bedridden. These issues generally revolve around the family genes and the environmental factors a person lives to survive (Duzel et al., 2016). Subsequently, the genetic changes, also called genetic variations, lead to complexity in that they can stand a chance to increase the risk or minimize the chances of one getting exposed to the dangers of developing AD. In recent research, many scientists can attest to more than 70 common regions affected by AD issues.
In the study by Ströhle et al. (2015) on variations of human genes associated with AD, there are only three significant findings on gene-related issues. In regular circumstances, it only occurs through inheritance, though the cases are not common, but the alterations of the genes also affect the next generation when such a problem occurs. In the APP gene, PSEN 1 and 2 can develop AD if a person lives beyond 65 years. It is not strictly 65 years that a person can start developing genetic-related AD issues, but in rare circumstances, some individuals undergo the problem at an earlier stage than 65 years (Bailey, 2013). At an earlier stage of life, before 65 years, it is realized that individuals who have Down syndrome can also stand a high risk of developing AD.
Due to too many chromosomes in the human body, a person is likely to be affected by the problem of Down syndrome. As a result, there are traces of APP in the body as a genetic risk factor for AD, which is related to the production of high levels of the protein amyloid precursor. Excess quantity of the protein results in a severe brain malfunction through building beta-amyloid plagues in the brain neurons (Khan et al., 2022). Suggestions from various estimations stipulate that more than half of individuals living with Down syndrome have a high chance of developing AD with appearing relating signs and symptoms at an early stage as 50 all their life to 60 years and above. As discussed earlier, the APOE genetic variations appear in many forms in the patient’s body. This makes it known to be the most influential factor that risks an individual’s life to get AD.
The APOE e4 is vital to the extent that it not only risks the chances of one getting AD but also promotes the infection at an early life stage. This effect covers a large population of individuals with genetic influence, while the APOE e2 may extend protection to an individual against AD. This clarifies the point that it may or may not increase or decrease the chances of an individual getting AD problems in life. Vincent (2010) found that environmental elements, changes in one’s lifestyle, variations in human genes, and other relevant biomedical issues play a significant role in the potential development of AD problems. The development of the disease is therefore not known as a result of the specific causing factors in the life of an aged individual.
Such receptors contribute minimally to the disease at the preliminary stages of life before severe infection. The reactive rates recognize a slow progressive accommodation of AD up to the late stages, where there is a provision of relief through the observable signs and symptoms in an individual, even if there is limited or no achievement of a specific cure (Sacco et al., 2016). Due to the above reasons, prevention and the most applicable technique for treatment starts through body exercise at the early stages to respond when the influence has minimal concentration. At the late stage of the disease, exercise is still an available and probable option. Still, it requires intense exercise from the victim to ensure that the response to the rate of concentration to the body is equalized, if not more than that of the disease, thereby increasing the patient’s safety and advancing the reduced rates of side effects.
Neurophysiology issues
In as much as exercise is the most preferred strategy to minimize the effect of the disease, research by Chainoglou and Hadjipavlou (2020) showed that other alternatives could be more reliable. Issues related to brain ageing, neuron alteration, and death through decline rates are only regulated by regular body exercise as the best applicable strategy. For this reason, great research studies have concentrated on psychological findings to understand the concept of brain ageing and the approaches to doing more body exercise to minimize the rate of the effect. The recent study provides a finding that concentrates on three significant areas in the larger human brain (Morello et al., 2018). Such sections include the hippocampal brain volumes, neurogenesis, and vascular brain physiology.
On the other hand, the degree of blood flow in the brain is directly associated with the infections of the brain ageing in a person and extends to cognition issues. Everything still revolves around the moderation of body exercise that keeps the brain awake to perform its functions at an average rate. The intense moderation of conducting exercise by the patients has been noticed to lead to acute blood augmentation to the flow in the human brain. Research studies by Scheltens et al. (2021) have also indicated that a high level of blood flow in the cerebral areas is experienced in many of the men who conduct regular and intense exercise than sedentary people. The results obtained from men who trained randomly for 12 weeks indicated that the cerebral part of the brain got sufficient rest in the degree of blood flow in the region covered by the anterior cingulate, as obtained from the group that indulged in intense exercise.
For the brain’s episodic memory, a study shows that the importance of infections at early stages of AD lies in the thought of applying the Hippocampal circuits. Large volumes of hippocampal circuits are believed to facilitate an improvement in the rate at which the cognitive functions in a person. Conducting moderate exercise from mild for more than one year minimises and prevents the degree of hippocampal atrophy volumes (Khan et al., 2022). Changes in hippocampal volumes are similar and correlated to the body’s fitness in cardiovascular changes. Another indication also provides that improving one’s cognitive performance depends on the degree of physical training, which increases the volumes of human hippocampal (Sattler et al., 2011). Neurogenesis in adult hippocampal also helps in learning processes and advancing a person’s brain memory level. It is difficult to determine the existence or level of neurogenesis in a person during the study of human beings. Still, there are pieces of evidence that rats show an excellent example of the improvement of neurogenesis hippocampal effects due to proper exercise. There is ongoing research to investigate and evaluate the techniques of testing and evaluating the human brain with elements of neurogenesis.
Prevention of Alzheimer’s Disease and Dementia
In the desire to reduce and treat the effects of AD, the intervention of a potential lifestyle calls for intense exercise in an individual with AD. Dementia is also directly associated with AD, and therefore exercise is a significant way to prevent such an effect at the primary level. High levels of prospective trials and epidemiological attempts give promising outcomes to address the problems caused and related to the hypothesis. An estimation of 54 per cent constitutes the risk factor where the individual can successfully prevent AD (Szeto, 2016). Healthcare professionals use relative risks in preexisting cases from meta-analysis to estimate the attributable risk of the AD population in the global space. The application concentrated on the seven main modifiable potential areas that constitute the risk factors of the disease. As a result, the high level of attributable risk depends on the rate at which one performs physical exercise (Barnes & Yaffe, 2011). The higher the risk attributed to the disease, the lower the rate of physical exercise and visevasa.
A prospective data operated on a large number of non-demented individuals to pool a relative rate of risk to the problems of dementia found that the category of the high rate of physical activity is necessary for low dementia. Indeed, exercise keeps many parties of the human body active and facilitates complete and confided blood flow in the brain and several body parts. The brain is one of the epicentres of a person’s life and an organ that facilitates thinking; several nerves are in the central nervous system (Young et al., 2015). Without sufficient blood flow, some of the nerves end up dying, leading to problems such as memory loss and impaired judgment in an individual. For this reason, one needs to participate in several physical body exercises to ensure the blood flow is sufficient and active in the brain, thereby minimizing the effects of diseases such as AD and dementia. The findings stipulated that the rate at which physical exercise and other related activities reduce the chances of getting AD and dementia diseases are 45 and 28 per cent, respectively.
In another trial that conducted a random control test to complete an extensive review of systemic analysis, the research indicated that physical exercise is of primary importance in regulating the impact of diseases. Between 1996 and late 2009, there were efforts to look at the associations where human physical exercise helps in regulative cognitive performance rate. For effective results, the research study must meet the meritocracy in sufficient size with maximized supervision to enhance an impactful control of the programs and groups (Norton et al., 2014). The demonstrations were significant ways to improve the available attention and speed in the processing rates. There is also a sufficient function of executive performance to improve the rate of brain memory in the groups that conducted regular exercises. As a result, the consistency in the effectiveness of an operating memory was noted in the groups with less exercise. In contrast, those with regular exercise had a high rate of memory. One essential element also realized in the research reliability and validity of the findings dwelled on the fact that the intensity of the exercise duration needed more significant consideration for realising the beneficial effects.
In previous discussions and research by reliable sources, there are elements of hippocampus decay among patients battling dementia. Regular exercise has since been found to regulate and minimize the rate of cortical decay amongst the old groups, and the existing relationship shows that there is interdependency in the volume of human hippocampal effects and physical body exercise (Khan et al., 2022). The application of MRI shows that most individuals with issues nondemented adults of older ages were higher and tripled the rate of the associations with the levels of one’s fitness, the large volume of hippocampal, and improved performance of the human spatial memory in the active people.
Alternatively, studies in the population-based concepts had prospective outcomes to demonstrate the significant benefits of conducting regular exercise to minimize the decline in cognitive level and dementia. A 14-year German study of population and other effects demonstrated that self-physical body activities among individuals reduce the chances of exposure to the risk of developing AD issues and MCI (Hamer & Chida, 2009). The results further showed that there is also improved and reliable performance in the degree of reactions and tests associated with neuropsychology.
Another trial test conducted by Chainoglou and Hadjipavlou (2020) to find out the prospective outcome in a daily measure for the hypothesis of activities could regularly give a prediction that there is an incidence of MCI and issues of AD. Active participation in regular exercise would also be essential in the regulatory measures to prevent diseases in people who might have fallen or are yet to fall victim. The study participants used wrist actigraphy to test the degree of complete physical activity, which was more reliable than the commonly used self-reports from the questionnaires. After a follow-up that critically took about four years, the association between the level of physical human activity and daily performance with the high cognitive decline and incidence of AD globally was determined (Svob et al., 2021). The risks of getting AD were reduced due to the more significant impacts of practising and subjecting the body to physical exercise. An eight-year study to determine the prospects of the same issue showed that most women who performed tasks daily and walked long distances had the minimum chance of getting affected by the disease. There was a minimized rate of cognitive issues, thereby declining during the study’s outcome.
A recent review also looked into how aerobic activities affect adults’ health in the concept of cognitive effects or outcomes. The main aim was to investigate, evaluate, and monitor the accounts of cardiovascular fitness in human beings for the cognition of an individual’s physical fitness. There were only considerations to areas with a fitness demonstration of cardiovascular, such as VO2 max in the test. There was no evidence of physical activities’ importance in relation to the cognitive domain due to body exercise. There is also an inclusion in the moderate level of bias in the high risk (Kumar & Singh, 2015). The study had been ignored where the intervention to facilitate human exercise was to realize the importance of increased fitness in human cardiovascular sections, including activities associated with aerobic light, lifting of body weights, and general stretching of the body exercises. The importance of this review dwells on individuals falling under specific sub-groupings, and the interpretation should be done with much understanding and caution to minimize errors and health-related issues. Other meta-analyses and systemic reviews indicate an improved and beneficial outcome with cognition exercise.
Antidepressants and Exercise as AD Treatment
Even though several research studies investigate the importance of exercise in the effectiveness of reduced cognitive impacts on patients battling the diseases, there is a need to consider the relevance of the evidence on exercise to minimize the rate of AD. Groups conducting randomized tests to supervise treatment have been limited to areas with significant challenges (Guzman et al., 2021). Many of the studies could have similarly looked into the existing population of the patients with the disease.
In one of the random control test trials that intended to eliminate most of the considerable issues through a severe assessment on whether the exercise program reduces the rate of ADL declining to the home base care nursing where residents had AD issues (Hoffmann et al., 2016). In the process, there was the intention to provide a daily service that took place for an average of one hour and twice a week to emphasize aerobic strength articulation, balancing, and flexible training models for one year. The findings stipulated that there was an increased rate of ADL decline where there were groups that did not conduct regular exercise. There was no significant result in the effect of disturbances in the behaviour, incidences of individual depression, or worrying scores of nutritional requirements.
Logically, Smith et al. (2010) found that it is notable that there is a complex nature of AD, making it challenging to identify and implement any form of treatment drug and interventions to treat individuals with the disease. Currently, several trials in clinical tests force scientists to develop and test many possible options as interventions to facilitate treatment. In as much as there is no defined cure for AD-related issues, there are several emergences of opinions and medical tests to treat the progressive disease targeting the preexisting issues and causes. Some medical and clinical trials stand chances to facilitate temporary improvement and stability to memory and critical thinking skills in a few individuals and manage signs and symptoms of problems associated with behavioural changes.
Additionally, individuals undergoing AD challenges may battle other issues such as sleeplessness, intense depression, high levels of anxiety, increased agitation, and signs and symptoms of behaviour and change in psychology. The ongoing studies dwell on the reasons for these signs and symptoms and explore new medical applications and strategies for using drugs in general management. Findings Morello et al. (2018) indicate that proper treatment of diseases makes life easy for the patients and the helpers since the performance of the tasks is done with effectiveness and understanding of sufficient conversation and good memory. After the strategical promotion of both emotional and physical comfort amongst the patients, such as minimizing incidences of stress, there can be administration of drugs such as anti-anxiety and psychotics. A conversation with a regular doctor will bring more effects and foster treatment in all situations.
In comparative research for the medical effects of both MCI and AD, the test worked against physical exercise, an effect to determine the impacts. The pharmacological approaches and physical exercise intervention proved the need for general treatment techniques (Scheltens et al., 2021). The moderation of exercise indicated a more substantial effect to pool the AD size more effectively than the MCI. The use of drugs with Cholinesterase with inhibitors in treatment and elements of memantine indicated less effect on AD cognition and no MCI effect. There was a high rate of discontinuation in the medication process and a lower level for the exercise.
In a look into the random trial of control between the moderate intensity to the highest level of aerobic patients’ exercise programs, there was an incident of mild AD (Chapman et al., 2013). In the performance of one-hour thrice weekly sessions for three weeks, regular cognitive performance was important without significant improvement in the scores of symptoms associated with neuropsychiatric issues. The study concentrated on issues of subject training programs and level of adherence, thereby the use to treat such models.
Findings by Khan et al. (2022) stipulate that longer interventional studies give high rates of expert compliance in the course breakdown to determine reliability. There is a need to consider the period of conducting an intervention to ensure an accurate finding and experience of the change. Another random study looking into an exercise of a supervised program found that there was an improved response in memory and delay during the training intervals. The cerebral outcome from the exercise demonstrated blood flow resting in the anterior cingulate regions. However, comparing adults with cognitive normality is not accessible for individuals with AD. The accuracy of studies related to AD and the effectiveness of the exercise can suffer a big blow when the sample size is smaller, respondents do not turn up, and they need more loyalty (Erickson et al., 2009). There must also be a follow-up on each event and an updated response. In a study that involved eight people in nine months to investigate MCI and an interval of three months of intervention during training, it was found that there was improved performance in cognitive results, which faded after the end of training programs; therefore, sufficiency in time and number is necessary.
Finally, in a recent research study examining how exercise affects dementia in older people, the meta-analysis findings indicated that the benefits had no clear outcome as evidence reliable on functional cognitive evidence. Chainoglou and Hadjipavlou (2020) found that the only benefit was based on the ADL’s ability to perform as a result of exercise, thereby proving the low-quality evidence of the heterogeneous study. Randomized meta-analysis test control trials impose a positive demonstration amongst AD patients undergoing exercise programs, leading to a decrease in cognitive decline rate with positive cognitive function in global setups. It is recommended that trials should be well designed to assess several types of severe dementia to improve the quality and general standards of further reviews.
Conclusion
Given the literature review and available research, it is logical to conclusively affirm that making specifications and recommendations that patients with Alzheimer’s disease should conduct regular exercise as a preventive approach is not substantive. The research studies are complex and heterogeneous regarding the existing variety of exercises to intervene in the accuracy of the findings. The author believes that institutions such as the American Heart Association and American College of Sports Medicine can facilitate substantial research and findings to cover potential benefits extensively. AD has been a medical challenge to the country and medical research institutions for many decades despite several attempts to find the most appropriate solution. Current evaluations of the disease, psychological reasons, and neuropathological considerations exist. The main target in the existing interventions is the treatment of the late stages of AD during the accumulation of severe mortality, high morbidity, and burdens imposed on the caregivers. Exercise is essential at both the early and late stages, even though it is not the only reliable solution for ultimate consideration. Prospective trials in large-scale volumes, meta-analyses, and systemic reviews demonstrate activity benefits. Unfortunately, several research studies and reviews undergo methodological problems and heterogeneous populations. Therefore, there is a need for more quality and highly randomized trials necessary for determining the potential aspect of exercise in the prevention and treatment of Alzheimer’s Disease.
References
Alzheimer’s Association. (2016). 2016 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 12(4), 459-509. https://www.sciencedirect.com/science/article/abs/pii/S1552526016000856
Bakulski, K. M., Seo, Y. A., Hickman, R. C., Brandt, D., Vadari, H. S., Hu, H., & Park, S. K.
(2020). Heavy Metals Exposure and Alzheimer’s Disease and Related Dementias.Journal of Alzheimer’s disease: JAD, 76(4), 1215–1242. https://doi.org/10.3233/JAD-200282
Bailey, D. M., Marley, C. J., Brugniaux, J. V., Hodson, D., New, K. J., Ogoh, S., & Ainslie, P. N. (2013). Elevated aerobic fitness sustained throughout the adult lifespan is associated with improved cerebral hemodynamics. Stroke, 44(11), 3235-3238. https://www.ahajournals.org/doi/full/10.1161/STROKEAHA.113.002589
Barnes, J. N. (2015). Exercise, cognitive function, and ageing. Advances in physiology education, 39(2), 55-62. https://journals.physiology.org/doi/full/10.1152/advan.00101.2014
Barnes, D. E., & Yaffe, K. (2011). The projected effect of risk factor reduction on Alzheimer’s disease prevalence. The Lancet Neurology, 10(9), 819-828. https://www.thelancet.com/journals/lancet/article/PIIS1474-4422(11)70072-2/fulltext
Buchman, A. S., Boyle, P. A., Yu, L., Shah, R. C., Wilson, R. S., & Bennett, D. A. (2012). Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology, 78(17), 1323-1329. https://www.neurology.org/doi/10.1212/wnl.0b013e3182535d35?wvsessionid=wv8150891d4c66414b883961f8e992e038
Chainoglou, E., & Hadjipavlou-Litina, D. (2020). Curcumin in Health and Diseases: Alzheimer’s Disease and Curcumin Analogues, Derivatives, and Hybrids. International journal of molecular sciences, 21(6), 1975. https://doi.org/10.3390/ijms21061975
Chapman, S. B., Aslan, S., Spence, J. S., DeFina, L. F., Keebler, M. W., Didehbani, N., & Lu, H. (2013). Shorter-term aerobic exercise improves brain, cognition, and cardiovascular fitness in ageing. Frontiers in aging neuroscience, 5, 75. https://www.frontiersin.org/articles/10.3389/fnagi.2013.00075/full
Duzel, E., van Praag, H., & Sendtner, M. (2016). Can physical exercise in old age improve memory and hippocampal function? Brain, 139(3), 662-673. https://academic.oup.com/brain/article/139/3/662/2468800
Erickson, K. I., Prakash, R. S., Voss, M. W., Chaddock, L., Hu, L., Morris, K. S., … & Kramer, A. F. (2009). Aerobic fitness is associated with hippocampal volume in elderly humans. Hippocampus, 19(10), 1030-1039. https://onlinelibrary.wiley.com/doi/abs/10.1002/hipo.20547
Farina, N., Rusted, J., & Tabet, N. (2014). The effect of exercise interventions on cognitive outcome in Alzheimer’s disease: a systematic review. International Psychogeriatrics, 26(1), 9-18. https://www.cambridge.org/core/journals/international-psychogeriatrics/article/abs/effect-of-exercise-interventions-on-cognitive-outcome-in-alzheimers-disease-a-systematic-review/49E5C885C501B58066A024CC114DADDF
Forbes, D., Forbes, S. C., Blake, C. M., Thiessen, E. J., & Forbes, S. (2015). Exercise programs for people with dementia. Cochrane database of systematic reviews, (4). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006489.pub4/full
Guzman-Martinez, L., Calfío, C., Farias, G. A., Vilches, C., Prieto, R., & Maccioni, R. B. (2021). New frontiers in the prevention, diagnosis, and treatment of Alzheimer’s disease. Journal of Alzheimer’s Disease, 82(s1), S51-S63. https://content.iospress.com/articles/journal-of-alzheimers-disease/jad201059
Hamer, M., & Chida, Y. (2009). Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychological medicine, 39(1), 3-11. https://www.cambridge.org/core/journals/psychological-medicine/article/abs/physical-activity-and-risk-of-neurodegenerative-disease-a-systematic-review-of-prospective-evidence/5FB109E05E85CF701F11FB6DBA9AE9B3
Hoffmann, K., Sobol, N. A., Frederiksen, K. S., Beyer, N., Vogel, A., Vestergaard, K., … & Hasselbalch, S. G. (2016). Moderate-to-high intensity physical exercise in patients with Alzheimer’s disease: a randomized controlled trial. Journal of Alzheimer’s Disease, 50(2), 443-453. https://content.iospress.com/articles/journal-of-alzheimers-disease/jad150817
Ketskes, N. (2023) ISNS CASE STUDY on Alzheimer’s Disease, ISNS.
Ketskés, N. and Rahm, C. (2023) Alzheimer’s Disease, ISNS Case Study. Available at: https://mail.google.com/mail/u/0/#inbox/FMfcgzGwJJVnPRkJXHwPGHWvGpckVVjq?projector=1.
Khan, F. Z., Mostaid, M. S., & Apu, M. N. H. (2022). Molecular signalling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease. Heliyon, 8(7), e09874. https://doi.org/10.1016/j.heliyon.2022.e09874
Kumar, A., & Singh, A. (2015). A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacological reports, 67(2), 195-203. https://www.sciencedirect.com/science/article/abs/pii/S1734114014002886
Morello, M., Landel, V., Lacassagne, E., Baranger, K., Annweiler, C., Féron, F., & Millet, P. (2018). Vitamin D Improves Neurogenesis and Cognition in a Mouse Model of Alzheimer’s Disease. Molecular neurobiology, 55(8), 6463–6479. https://doi.org/10.1007/s12035-017-0839-1
Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K., & Brayne, C. (2014). Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. The Lancet Neurology, 13(8), 788-794. https://www.thelancet.com/journals/a/article/PIIS1474-4422%2814%2970136-X/fulltext
Rahm, C. (2023) BIOHACKING THROUGH CHEMISTRY with DRC Ventures solutions for deep-rooted causes. , BIOHACKING THROUGH CHEMISTRY.
Rolland, Y., Pillard, F., Klapouszczak, A., Reynish, E., Thomas, D., Andrieu, S., … & Vellas, B. (2007). Exercise program for nursing home residents with Alzheimer’s disease: A 1‐year randomized, controlled trial. Journal of the American Geriatrics Society, 55(2), 158-165. https://agsjournals.onlinelibrary.wiley.com/doi/abs/10.1111/j.1532-5415.2007.01035.x
Ryan, S. M., & Nolan, Y. M. (2016). Neuroinflammation negatively affects adult hippocampal neurogenesis and cognition: can exercise compensate? Neuroscience & Biobehavioral Reviews, 61, 121-131. https://www.sciencedirect.com/science/article/abs/pii/S014976341530049X
Sacco, G., Caillaud, C., Ben Sadoun, G., Robert, P., David, R., & Brisswalter, J. (2016). Exercise plus cognitive performance over and above exercise alone in subjects with mild cognitive impairment. Journal of Alzheimer’s Disease, 50(1), 19-25. https://content.iospress.com/articles/journal-of-alzheimers-disease/jad150194
Sattler, C., Erickson, K. I., Toro, P., & Schröder, J. (2011). Physical fitness as a protective factor for cognitive impairment in a prospective population-based study in Germany. Journal of Alzheimer’s Disease, 26(4), 709-718. https://content.iospress.com/articles/journal-of-alzheimers-disease/jad110548
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., … & van der Flier, W. M. (2021). Alzheimer’s disease. The Lancet, 397(10284), 1577-1590. https://www.thelancet.com/article/S0140-6736(20)32205-4/fulltext
Smith, P. J., Blumenthal, J. A., Hoffman, B. M., Cooper, H., Strauman, T. A., Welsh-Bohmer, K., … & Sherwood, A. (2010). Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosomatic medicine, 72(3), 239. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897704/
Ströhle, A., Schmidt, D. K., Schultz, F., Fricke, N., Staden, T., Hellweg, R., … & Rieckmann, N. (2015). Drug and exercise treatment of Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis of effects on cognition in randomized controlled trials. The American Journal of Geriatric Psychiatry, 23(12), 1234-1249. https://www.sciencedirect.com/science/article/abs/pii/S1064748115002134
Svob Strac, D., Konjevod, M., Sagud, M., Nikolac Perkovic, M., Nedic Erjavec, G., Vuic, B., … & Pivac, N. (2021). Personalizing the Care and Treatment of Alzheimer’s Disease: An Overview. Pharmacogenomics and Personalized Medicine, 631-653. https://www.tandfonline.com/doi/full/10.2147/PGPM.S284615
Szeto, J. Y. SJ Lewis Current treatment options for Alzheimer’s and Parkinson’s disease dementia., (2016),14. DOI: https://doi.org/10.2174/1570159X14666151208112754.PMID: https://www.ncbi.nlmnih.gov/pubmed/26644155,326-338
Vincent, G. K. (2010). The next four decades: The older population in the United States: 2010 to 2050 (No. 1138). US Department of Commerce, Economics and Statistics Administration, US Census Bureau. https://books.google.co.ke/books?hl=en&lr=&id=gALA2NWAFZ4C&oi=fnd&ots=iN3QF-_zT8&sig=JKYvsZGVs-iT2rRpxgy4PBpoYIc&redir_esc=y
Young, J., Angevaren, M., Rusted, J., & Tabet, N. (2015). Aerobic exercise to improve cognitive function in older people without known cognitive impairment. Cochrane Database of Systematic Reviews, (4). https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005381.pub4/abstract
write